Comparison of metallothionein-overexpression with sentinel lymph node biopsy as prognostic factors in melanoma

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 5, 2007, Pages 669-677

  Weinlich, Georg ^a   Topar, G ^a   Eisendle, K ^a   Fritsch, P O ^a   Zelger, B ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Melanoma; Metallothionein; Prognostic factor; Sentinel lymph node biopsy

Indexed keywords

METALLOTHIONEIN; MONOCLONAL ANTIBODY; PARAFFIN;

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; CALCULATION; CANCER GROWTH; CHI SQUARE TEST; CONTROLLED STUDY; DEATH; DISEASE FREE SURVIVAL; FEMALE; FISHER EXACT TEST; FOLLOW UP; GENE OVEREXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SENTINEL LYMPH NODE BIOPSY; STATISTICAL SIGNIFICANCE; UNIVARIATE ANALYSIS; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; CHILD; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; METALLOTHIONEIN; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 34250355935     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.02051.x     Document Type: Article

References (55)

1. Morton DL, Wen DR, Wong JH et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-399.
2. Morton DL, Cochran AJ, Thompson JF et al. Sentinel node biopsy for early-stage melanoma: Accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005; 242: 302-311.
3. Cherpelis BS, Haddad F, Messina J et al. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. J Am Acad Dermatol 2001; 44: 762-766.
4. Topar G, Eisendle K, Zelger B, Fritsch P. Sentinel lymph node status in melanoma - a valuable prognostic factor? Br J Dermatol 2006; 154: 1080-1087.
5. Gershenwald JE, Thompson W, Mansfield PF et al. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17: 976-983.
6. Reintgen D. More rational and conservative surgical strategies for malignant melanoma using lymphatic mapping and sentinel node biopsy techniques. Curr Opin Oncol 1996; 8: 152-158.
7. Harlow SP, Krag DN, Ashikaga T et al. Gamma probe guided biopsy of the sentinel node in malignant melanoma: A multicentre study. Melanoma Res 2001; 11: 45-55.
8. Lowe JB, Hurst E, Moley JF, Cornelius LA. Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol 2003; 139: 617-621.
9. Roka F, Kittler H, Cauzig P et al. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis. Br J Cancer 2005; 92: 662-667.
10. Nath R, Kambadur R, Gulati S, Paliwal VK, Sharma M. Molecular aspects, physiological functions, and clinical significance of metallothioneins. Crit Rev Food Sci Nutr 1988; 27: 41-85.
11. Miles AT, Hawksworth GM, Beattie JH, Rodilla V. Induction, regulation, degradation, and biological significance of mammalian metallothioneins. Crit Rev Biochem Mol Biol 2000; 35: 35-70.
12. Nordberg M, Nordberg GF. Toxicological aspects of metallothionein. Cell Mol Biol 2000; 46: 451-463.
13. Simpkins CO. Metallothionein in human disease. Cell Mol Biol 2000; 46: 465-488.
14. Hanada K, Sawamura D, Tamai K et al. Novel function of metallothionein in photoprotection: Metallothionein-null mouse exhibits reduced tolerance against ultraviolet B injury in the skin. J Invest Dermatol 1998; 111: 582-585.
15. Hansen C, Ablett E, Green A et al. Biphasic response of the metallothionein promoter to ultraviolet radiation in human melanoma cells. Photochem Photobiol 1997; 65: 550-555.
16. Reeve VE, Nishimura N, Bosnic M, Michalska AE, Choo KH. Lack of metallothionein-I and -II exacerbates the immunosuppressive effect of ultraviolet B radiation and cis-urocanic acid in mice. Immunology 2000; 100: 399-404.
17. Okazaki Y, Miura N, Satoh M, Imura N, Naganuma A. Metallothionein-mediated resistance to multiple drugs can be induced by several anticancer drugs in mice. Biochem Biophys Res Commun 1998; 245: 815-818.
18. Hishikawa Y, Abe S, Kinugasa S et al. Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in oesophageal cancer. Oncology 1997; 54: 342-347.
19. Chin JL, Banerjee D, Kadhim SA et al. Metallothionein in testicular germ cell tumours and drug resistance. Clinical correlation. Cancer 1993; 72: 3029-3035.
20. Sunada F, Itabashi M, Ohkura H, Okumura T. p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy. World J Gastroenterol 2005; 11: 5696-5700.
21. Tsangaris GT, Tzortzatou-Stathopoulou F. Metallothionein expression prevents apoptosis: A study with antisense phosphorothioate oligodeoxynucleotides in a human T cell line. Anticancer Res 1998; 18: 2423-2434.
22. Karin M, Imbra RJ, Heguy A, Wong G. Interleukin 1 regulates human metallothionein gene expression. Mol Cell Biol 1985; 5: 2866-2869.
23. Nishimura N, Reeve VE, Nishimura H, Satoh M, Tohyama C. Cutaneous metallothionein induction by ultraviolet B irradiation in interleukin-6 null mice. J Invest Dermatol 2000; 114: 343-348.
24. Schroeder JJ, Cousins RJ. Interleukin-6 regulates metallothionein gene expression and zinc metabolism in hepatocyte monolayer cultures. Proc Natl Acad Sci USA 1990; 87: 3137-3141.
25. Sato M, Sasaki M. Tissue-specific induction of metallothionein synthesis by tumour necrosis factor α. Res Commun Chem Pathol Pharmacol 1992; 75: 159-172.
26. 3 in cultured cells and in mice. Proc Natl Acad Sci USA 1987; 84: 8810-8813.
27. Cherian MG, Jayasurya A, Bay BH. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 2003; 533: 201-209.
28. Surowiak P, Materna V, Kaplenko I et al. Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch 2005; 447: 626-633.
29. Mitropoulos D, Kyroudi-Voulgari A et al. Prognostic significance of metallothionein expression in renal cell carcinoma. World J Surg Oncol 2005; 3: 5.
30. Jin R, Huang J, Tan PH, Bay BH. Clinicopathological significance of metallothioneins in breast cancer. Pathol Oncol Res 2004; 10: 74-79.
31. Dziegiel P, Jelen M, Muszczynska B et al. Role of metallothionein expression in non-small cell lung carcinomas. Rocz Akad Med Bialymst 2004; 49: 43-45.
32. Sauerbrey A, Zintl F, Volm M. Expression of metallothionein in initial and relapsed childhood acute lymphoblastic leukemia. Ann Hematol 1994; 69: 111-115.
33. Ohshio G, Imamura T, Okada N et al. Immunohistochemical study of metallothionein in pancreatic carcinomas. J Cancer Res Clin Oncol 1996; 122: 351-355.
34. Shukla VK, Aryya NC, Pitale A et al. Metallothionein expression in carcinoma of the gallbladder. Histopathology 1998; 33: 154-157.
35. Zelger B, Hittmair A, Schir M et al. Immunohistochemically demonstrated metallothionein expression in malignant melanoma. Histopathology 1993; 23: 257-263.
36. Goldmann T, Ribbert D, Suter L, Brode M, Otto F. Tumour characteristics involved in the metastatic behaviour as an improvement in primary cutaneous melanoma prognostics. J Exp Clin Cancer Res 1998; 17: 483-489.
37. Sugita K, Yamamoto O, Asahi M. Immunohistochemical analysis of metallothionein expression in malignant melanoma in Japanese patients. Am J Dermatopathol 2001; 23: 29-35.
38. Zelger B, Sidoroff A, Höpfl R, Öfner D, Jasani B, Schmid KW. Metallothionein expression in nonmelanoma skin cancer. An immunohistochemical study. Appl Immunohistochem 1994; 2: 254-260.
39. Rossen K, Haerslev T, Hou-Jensen K, Jacobsen GK. Metallothionein expression in basaloid proliferations overlying dermatofibromas and in basal cell carcinomas. Br J Dermatol 1997; 136: 30-34.
40. Otto FJ, Goldmann T, Biess B, Lippold A, Suter L, Westhoff U. Prognostic classification of malignant melanomas by combining clinical, histological, and immunohistochemical parameters. Oncology 1999; 56: 208-214.
41. Tuccari G, Fedele F, Giuffre G, Trombetta CJ, Barresi G. Immunohistochemical demonstration of metallothionein in eyes with choroidal melanomas. Eur J Ophthalmol 2000; 10: 312-317.
42. Weinlich G, Bitterlich W, Mayr V, Fritsch PO, Zelger B. Metallothionein-overexpression as a prognostic factor for progression and survival in melanoma. A prospective study on 520 patients. Br J Dermatol 2003; 149: 535-541.
43. Weinlich G, Eisendle K, Hassler E, Baltaci M, Fritsch PO, Zelger B. Metallothionein-overexpression as a highly significant prognostic factor in melanoma. A prospective study on 1270 patients. Br J Oncol 2006; 94: 835-841.
44. Morton DL, Thompson JF, Essner R et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999; 230: 453-463.
45. Leong SP, Steinmetz I, Habib FA et al. Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg 1997; 132: 666-672.
46. Evering WE, Haywood S, Elmes ME, Jasani B, Trafford J. Histochemical and immunocytochemical evaluation of copper and metallothionein in the liver and kidney of copper-loaded rats. J Pathol 1990; 160: 305-312.
47. Jasani B, Elmes ME. Immunohistochemical detection of metallothionein. Meth Enzymol 1991; 205: 95-107.
48. van den Oord JJ, De Ley M. Distribution of metallothionein in normal and pathological human skin. Arch Dermatol Res 1994; 286: 62-68.
49. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
50. Spiegel MR. Statistik, 2nd edn. McGraw-Hill Book Company, Hamburg, 1990.
51. Morton DL, Hoon DS, Cochran AJ et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: Therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003; 238: 538-549; discussion 549 -50.
52. Kretschmer L, Hilgers R, Mohrle M et al. Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. Eur J Cancer 2004; 40: 212-218.
53. Zelger B, Sidoroff A. Anti-metallothionein labeling. Am J Surg Pathol 1996; 20: 253-257.
54. Meier F, Will S, Ellwanger U et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002; 147: 62-70.
55. Markowitz JS, Cosimi LA, Carey RW et al. Prognosis after initial recurrence of cutaneous melanoma. Arch Surg 1991; 126: 703-707; discussion 707-708.